Outcomes of Percutaneous Balloon Mitral Valvuloplasty in Significant Mitral Stenosis with Moderate Mitral Regurgitation - Single Center Study

Abstract

Objective:Rheumatic heart disease is the deposition of immune complexes which cause malfunction of the heart valves. Percutaneous mitral balloon valvuloplasty (PMBV) is an established treatment option in patients with symptomatic moderate or severe rheumatic mitral valve disease, but PMBV is not a preferred option in mitral stenosis (MS) patients with moderate mitral regurgitation (MR) due to the risk of severe MR. The aim of this study was to evaluate the safety and feasibility of PMBV in symptomatic MS patients with moderate MR by comparing the post-procedural parameters with those of MS patients with mild or no MR.Method:Among 104 patients with symptomatic MS, 10 patients with moderate MR were classified as group 2 while 94 patients who had mild or none MR were classified as group 1 in the present work. All patients underwent PMBV and pre- and post-procedural mitral valve area, MRs were recorded and cardiovascular events and complications were assessed in 30 days.Results:The only difference in both groups before and after the procedure was the severity of the MR. Cardiovascular death was not observed for both groups in 30 days. In group 1, there were 3 patients and in group 2, there was 1 patient who developed severe MR after PMBV. All patients who had post-procedural severe MR required mitral valve replacement in 30 days due to severe MR in group 1. The composite complication rate was similar between the groups.Conclusion:PMBV might be an alternative treatment option for selected patients having significant MS with moderate MR.

Keywords

• mitral valve regurgitation
• mitral valve stenosis
• mitral valve valvuloplasty